FDA Injunction Defense Attorney: When FDA Escalates to Federal Court
An FDA injunction is the moment a regulatory problem leaves the administrative lane and enters federal court. For many companies, that is the most dangerous stage short of a criminal indictment. The government is no longer asking for voluntary correction. It is asking a judge to force compliance, stop operations, restrict distribution, or lock the company into a court-supervised consent decree.
If you are searching for an FDA injunction defense attorney or FDA consent decree defense, the situation is already serious enough that ordinary compliance counsel may not be enough.
What is an FDA injunction?
An injunction is a court order directing a defendant to do something the law requires—or forbidding conduct the law prohibits. In FDA matters, the government may seek an injunction through DOJ to stop products from entering interstate commerce, shut down violative operations, or compel corrective action.
When injunctions are resolved by agreement, the result is often a consent decree. That is not simply a settlement handshake. It is a binding federal court order, typically with ongoing obligations, reporting requirements, outside-expert oversight, operational conditions, and steep consequences for future noncompliance.
How companies end up facing an injunction
Injunction cases usually do not arise out of nowhere. Common paths include:
- repeated inspectional findings,
- failed remediation,
- warning letters that FDA considers inadequately addressed,
- ongoing CGMP or quality-system failures,
- illegal marketing or distribution,
- serious public-health concerns,
- repeated imports or releases of violative products,
- conduct FDA views as persistent or knowingly continued.
Sometimes the company sees the injunction coming. Sometimes it does not fully understand the risk until DOJ files in federal court.
Why injunctions are so disruptive
A warning letter hurts. An injunction can threaten the company’s ability to function.
Possible consequences include:
- operational shutdown,
- product holds,
- outside expert certification,
- reinspection requirements,
- costly remediation plans,
- limits on future manufacturing or distribution,
- contempt exposure if the decree is violated,
- collateral damage with customers, investors, and payers.
The injunction stage is also where the record built during inspections, 483s, warning letters, recalls, and management communications becomes crucial. The government will use that history to argue that voluntary compliance has failed.
What defense strategy looks like at the injunction stage
1. Reconstruct the regulatory record
What did FDA observe, request, warn about, and follow up on? What did the company say and do?
2. Test the government’s theory
Not every alleged violation justifies the relief the government seeks. Scope matters.
3. Evaluate operational reality
Can the company comply with proposed terms? Some “fixes” sound reasonable on paper but are business-ending in practice.
4. Coordinate technical and litigation teams
You cannot defend an injunction case without understanding the science, quality systems, manufacturing or distribution process, and the legal standard for relief.
5. Prepare for life after the hearing
Even if the matter resolves by consent decree, the practical battle often continues through compliance, reporting, and monitoring.
Stem cell, compounding, and manufacturing businesses should pay special attention
FDA has already shown it will use injunction litigation in high-profile stem cell and regenerative-medicine cases when it believes clinics or businesses are marketing unapproved products and have not come into compliance. The same general escalation logic applies in compounding, manufacturing, import, device, and misbranding cases when FDA concludes the risk is ongoing.
That is one reason companies should treat warning-letter and inspection responses as if they may later be read by a federal judge.
Why Ronald W. Chapman II is a strong choice for injunction and consent decree defense
Injunction cases require courtroom strength, not just regulatory vocabulary.
Ronald W. Chapman II is a former federal prosecutor and U.S. Marine Corps Judge Advocate with an LL.M. in Health Care Law. His practice is focused on high-stakes federal defense for professionals and regulated entities, and his track record in healthcare fraud and other complex federal matters demonstrates the trial readiness that injunction defense demands.
That matters because injunction cases are about leverage. The government relies on history, documents, and technical complexity to narrow a defendant’s options. A lawyer with experience dismantling federal enforcement narratives is better positioned to challenge the scope of relief, negotiate realistic terms, and defend the client if the matter cannot be resolved quietly.
At Chapman, Dowling & Mallek, injunction defense means fighting on both fronts: the legal front in federal court and the practical front of protecting the client’s ability to survive the enforcement action.
FAQ
Is a consent decree better than fighting?
Sometimes. Sometimes not. The critical question is whether the proposed terms are realistic and strategically acceptable.
Can an injunction happen without a criminal case?
Yes. Injunctions are civil judicial actions, though the same facts can create criminal risk in some matters.
What if we already received a warning letter?
That history matters a great deal. It will likely be part of the government’s case for why stronger relief is necessary.
Call to action: If FDA and DOJ are moving toward an injunction or consent decree, the right defense is one built for court, not just correspondence.